The Belgian severe @entity565 registry is a web-based registry encompassing demographic, clinical, functional and inflammatory data of severe @entity748 (SA), aiming at improving awareness, knowledge on its natural history and subphenotypes, and offering tools to optimize care of this @entity565 population. METHODS: The cross-sectional analyses of this registry included 350 SA as defined by the ATS (2000) from 9 Belgian centres, with at least one year follow up. RESULTS: Mean age was 55      14  yrs. SA were more frequently female (57%) and @entity1097 (70%). Late-onset @entity565 (>= 40  yr) was observed in 31% of SA. Current smokers represented 12% while 31% were ex-smokers. In addition to high doses ICS  +  LABA, 65% of @entity1 were receiving @entity21292 , 27% anti-IgE and 24% maintenance oral @entity288 (8  mg (Interquartile range-IQR:4-8) @entity1667 ). Despite impaired airflow (median FEV1:67%; IQR: 52-81) only 65% had a post-bronchodilator FEV1/FVC ratio <70%. The median blood eosinophil count was 240/mm  . The median FENO was 26  ppb (IQR: 15-43) and 22% of SA had FENO  >=   50  ppb. Induced sputum was successful in 86 @entity1 . @entity1712 (sputum Eos  >=   3%) was the predominant phenotype (55%) while neutrophilic (sputum @entity331  >=   76%) and paucigranulocytic @entity565 accounted for 22% and 17% respectively. Comorbidities included @entity2490 and chronic rhinosinusitis (49%), @entity1412 (19%), @entity354 (36%), overweight and @entity28 (47%) and @entity308 (19%). In addition, 8% had @entity117 -induced @entity565 and 3% @entity17178 . Asthma was not well-controlled in 83% according to ACT  <  20 and 77% with ACQ  >  1.5. CONCLUSION: In this cohort of @entity1 with severe @entity565 , the majority displayed indices of persistent airflow limitation and eosinophilic @entity32 despite high-dose @entity288 , suggesting potential for eosinophil-targeted biotherapies.

Heterogeneity of phenotypes in severe XXXX . The Belgian Severe Asthma Registry (BSAR).

@entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatics'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone'] @entity1712 :: ('MESH:D004802', 'Disease') :: ['Eosinophilic asthma'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1097 :: ('MESH:C566404', 'Disease') :: ['atopic'] @entity21292 :: ('CHEBI:49159', 'Chemical') :: ['LTRA'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis'] @entity331 :: ('CHEBI:23995', 'Chemical') :: ['Neu'] @entity354 :: ('MESH:D005764', 'Disease') :: ['oesophageal reflux'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['nasal polyposis'] @entity17178 :: ('2318', 'Gene') :: ['ABPA'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity748 :: (MESH:D013224,Disease) :: ['asthmatics']
